Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 --...

Related Keywords

Elizabeth Coleman ,John Menditto ,Corporate Communications ,Lisata Therapeutics Inc ,European Medicines Agency ,Nasdaq ,European Union ,Exchange Commission ,Paediatric Committee ,Paediatric Investigation Plan ,Executive Vice President ,Chief Medical Officer ,Paediatric Regulation ,Fast Track ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Investor Relations ,